PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

Citation data:

Oncotarget, ISSN: 1949-2553, Vol: 9, Issue: 44, Page: 27460-27470

Publication Year:
2018
Usage 2
Downloads 1
Abstract Views 1
Captures 21
Readers 21
Mentions 1
News Mentions 1
Social Media 3
Tweets 3
Citations 4
Citation Indexes 4
Repository URL:
https://escholarship.umassmed.edu/oapubs/3498
PMID:
29937998; 27276705
DOI:
10.18632/oncotarget.25446; 10.18632/oncotarget.8548
PMCID:
PMC5129944
Author(s):
Rolfes, Verena; Idel, Christian; Pries, Ralph; Plotze-Martin, Kirstin; Habermann, Jens; Gemoll, Timo; Bohnet, Sabine; Latz, Eicke; Ribbat-Idel, Julika; Franklin, Bernardo S.; Wollenberg, Barbara Show More Hide
Publisher(s):
Impact Journals, LLC
Tags:
Medicine; atezolizumab; biomarkers for PD1-PD-L1 checkpoint therapy; head and neck cancer; tumor-educated platelets; Cancer Biology; Immunoprophylaxis and Therapy; Neoplasms; Therapeutics
Most Recent Tweet View All Tweets
Most Recent News Mention
article description
Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patients with various cancer types. However, there is still a large fraction of patients that do not respond to checkpoint inhibitors, and the challenge remains to find cellular and molecular cues that could predict which patients would benefit from these therapies. Using a series of qualitative and quantitative methods we show here that PBMCs and platelets from smokers and patients with head and neck squamous cell carcinoma (HNSCC) or lung cancer express and up-regulate PD-L1 independently of tumor stage. Furthermore, treatment with Atezolizumab, a fully humanised monoclonal antibody against PD-L1, in 4 patients with lung cancer caused a decrease in PD-L1 expression in platelets, which was restored over 20 days. Altogether, our findings reveal the expression of the main therapeutic target in current checkpoint therapies in human platelets and highlight their potential as biomarkers to predict successful therapeutic outcomes.